Answers are grounded in this paper and cite their sources.
Objectives: Designer Receptors Exclusively Activated by Designer Drug (DREADDs) is one of the chemogenetic technologies that afford a means to selectively and remotely control the activity of neuronal population expressing ''designer receptor'' by systemic delivery of the biologically inert compound.Muscarinic-based designer receptors, hM 3 Dq (excitatory) and hM 4 Di (inhibitory), can be activated by clozapine-N-oxide (CNO), are most widely used.DREADDs can be applicable for larger and discontinuous brain tissues, which non-human primate studies demand.For the application of DREADD to monkey study, it is desirable to monitor the DREADD expression in vivo.In addition, CNO has modest brain permeability and can be metabolized to clozapine, which is also a potent DREADD agonist.Since clozapine possesses activity at sites for numerous endogenous receptors, the CNO administration could be associated with off-target actions.In this study, we demonstrated that a novel ligand, deschloroclozapine (DCZ), served a dual purpose in chemogenetics: (1) as a selective compound for visualization of DREADD expression in vivo by positron emission tomography
No takes yet. Share an insight, caveat, or question.
Lange et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: